

Abstract 432P: Country and gender representation in abstracts at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO AM)

Laure-Anne Teuwen^a, Joanna Young^b, Amy Davies^{c,*}, Jo Hudson^d, Maria T Bourlon^e, Hans Prenen^a, Eva Segelov^{c,f}

Background:

- There is a paucity of data describing authorship of clinical trial abstracts through the lens of country and gender representation¹⁻⁶
- It is not clear whether research is representative of the global oncology community¹⁻⁶

Methods:

- We analyzed the country and gender of first and last authors across 247 solid tumor phase 3 trial abstracts presented at the 2022 ASCO AM, the largest oncology meeting in the world
- Countries were categorized by region and income according to World Bank analytical grouping

Results:

- North America, Europe & Central Asia and East Asia & Pacific were the best represented regions (48%, 29%, 19% for first author, and 40%, 36%, 21% for last author respectively)
- Most authors in Asia originated from institutions in China. In Asia, first and last authors were more likely to be male (72% and 66% respectively)
- There were no last authors representing Latin America




Figure 1: Regional representation across solid tumor phase 3 trial abstracts




Figure 2: Gender representation across solid tumor phase 3 trial abstracts according to region




Figure 3: Representation across solid tumor phase 3 trial abstracts according to country's income categorization

Conclusions:

- Most trials at the 2022 ASCO AM were presented by males from institutions in high income, Western countries.
- Authors from low and middle income countries, females, and countries with the highest cancer burden are under represented.
- Given the projected greatest relative increase in cancer burden in low and medium development index countries in the next 20 years, it is increasingly essential to tailor research approaches to areas of highest need.
- Author diversity is important to foster innovative approaches to promote pragmatic solutions to the major dilemmas in oncology around the globe.

Affiliations: (a) University Hospital Antwerp (b) Blue Ridge Cancer Care (c) Monash University (d) Monash Health (e) Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (f) University of Bern.

References: (1) Dymanus 2021 (2) Hornstein 2022 (3) Jagsi 2009 (4) Grandis 2022 (5) Odedina 2020 (6) Rolfo 2016.